Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-049-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin sensitization (OECD TG 429): sensitizing (read across from Ylang Ylang I (Ylang Ylang extra EO Comores))
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 August 2006 - 5 September 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 2002
- Deviations:
- no
- Remarks:
- Remarks: No dose selection rationale is provided. Information on solubility of the substance in the solvent is not given.
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Ylang Ylang extra EO Comores
- CTL test substance reference No: Y13877/001
- Expiration date of the lot/batch: June 2007
- Physical state: liquid
- Colour: yellow
- Analytical purity: not specified (pure material)
- Storage condition of test material: ambient temperature in the dark - Species:
- mouse
- Strain:
- other: CBA/Ca/Ola/Hsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan UK Limited, Shaw's Farm, Blackthorne, Bicester, Oxon, UK
- Age at study initiation: 8-12 weeks
- Housing: 4 mice/cage, suitable cages
- Diet: ad libitum, RM1 by Special Diet Services Limited, Witham, Essex, UK
- Water: ad libitum
- Acclimation period: 5 days prior dosing
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3
- Humidity (%): 30-70
- Air changes (per hr): min 15
- Photoperiod (hrs dark / hrs light): 12 - Vehicle:
- other: 1:3 ethanol:diethylphthalate
- Concentration:
- 0.5, 1, 2.5, 5 and 10% (w/v)
- No. of animals per dose:
- 4
- Details on study design:
- MAIN STUDY
TREATMENT PREPARATION AND ADMINISTRATION:
25 µl of the substance was applied on the dorsal ear with a micro-pipette (injection), once for three consecutive days. Dose preparations were used within 24 hours. Three days after last treatment, 250 µl PBS 20 µCi/mmol specific activity 3H-methyl thymidine, were injected in the tail vein. Five hours thereafter the animals were sacrificed.
Cell suspension: mechanical disaggregation of pooled lymph nodes; properly prepared as described in the Guideline OECD 429.
Incorporation of 3H-methyl thymidine was measured by β-scintillation (disintegrations/min: DPM).
Criteria used to consider a positive response:
- Stimulation Index (SI) was calculated as Disintegrations per min (DPM) per concentration/DPM vehicle control. A positive response is indiated when the SI ≥ 3.
- The EC3 is the concentration for which a 3- fold increase in DPM is seen. The EC3 is calculated as follows: [(3-d)/(b-d)]* (a-c)+c, where a: concentration giving the SI immediately higher than 3, b: SI of a, c: concentration giving an SI immediately below 3, d: SI of c - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Positive control results:
- The stimulation index at tested concentrations 5, 10 and 25% w/v were 1.7, 2.3, 6.4, respectively. This result confirms the validity of the test.
- Key result
- Parameter:
- EC3
- Remarks:
- %
- Value:
- 6.8
- Parameter:
- SI
- Value:
- 1.5
- Test group / Remarks:
- 0.5% concentration
- Parameter:
- SI
- Value:
- 1.4
- Test group / Remarks:
- 1% concentration
- Parameter:
- SI
- Value:
- 2.1
- Test group / Remarks:
- 2.5% concentration
- Parameter:
- SI
- Value:
- 2.5
- Test group / Remarks:
- 5% concentration
- Parameter:
- SI
- Value:
- 3.9
- Test group / Remarks:
- 10% concentration
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
Ylang Ylang Extra EO comores induced a higher than 3-fold increase in lympocyte proliferation at the highest concentration tested (10% w/v).
DETAILS ON STIMULATION INDEX CALCULATION
Mean disintegrations per minute (DPM) values were:
- Vehicle control: 533
- 0.5%: 805
- 1%: 742
- 2.5%: 1099
- 5%: 1331
- 10%: 2090
EC3 CALCULATION
The calculated EC3 was 6.8%.
CLINICAL OBSERVATIONS:
No visual levels of skin irritancy were observed at any of the concentrations used on or around the esar area for the duration of the study.
BODY WEIGHTS
Body weights were recorded but showed no abnormalities. - Interpretation of results:
- other: Skin Sensitiser 1B
- Remarks:
- Based on CLP criteria (Annex I of 1272/2008/EC)
- Conclusions:
- Ylang Ylang Extra EO comores induced a higher than 3-fold increase in lympocyte proliferation at the highest concentration tested (10% w/v). The calculated EC3 was 6.8%. Under the conditions of this assay, the test substance is needs to be classified as Skin Sensitiser Category 1B in accordance with Annex I of the CLP Regulation (1272/2008/EC).
- Executive summary:
A Local Lymph Node Assay (LLNA) was performed according to the OECD guideline 429 (2002). Four mice per group were treated with 0%, 0.5%, 1%, 2.5%, 5%, and 10% w/v Ylang Ylang Extra EO Comores in 1:3 ethanol:diethyl phthalate (vehicle) for three consecutive days, followed by in vivo radiolabelling (by injection) and lymphocyte proliferation analysis with the liquid scintillation counter. The number of disintegrations per minute (dpm) was determined for each group for the pooled lymph nodes. Treatment with Ylang Ylang Extra EO Comores did induce significantly the lymph node proliferation in mice as compared to controls at the highest dose tested. A higher than 3-fold increase in lympocyte proliferation was found at the highest concentration tested (10% w/v). The calculated EC3 was 6.8%. Under the conditions of this assay, the test substance is needs to be classified as Skin Sensitiser Category 1B in accordance with Annex I of the CLP Regulation (1272/2008/EC).
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- The justification document for read-across is attached to this record.
05 February 2018 READ-ACROSS STUDY / YLANG YLANG III OIL - SKIN SENSITISATION I&B9W8768R001F0.2
According to Annex VII, 8.3 of the REACh Regulation (EC) No 1907/2006, skin sensitisation is standard information required for the registration of substances manufactured or imported in quantities of one tonne per year or more. However, according to Annex XI, 1.5 of the REACH Regulation, Read-across and grouping approaches can be used to adapt the standard testing regime. This read-across study report follows notably the recommendations made by the European Chemicals Agency in its “Guidance on information requirements and chemical safety assessment Chapter R.6 – QSARs and grouping of chemicals” (ECHA, 2008) and in its document “Read-Across Assessment Framework (RAAF)” (ECHA, 2017).
A read-across approach appears appropriate to predict the endpoint “skin sensitisation” for the substance Ylang Ylang III oil because:
An LLNA study, according to OECD test guideline 429, is available for the substance Ylang Ylang Ext, which composition is very similar to the target substance.
Ylang Ylang Ext /I /II oil and Ylang Ylang III oil, are very similar in composition and show mainly variations in concentrations of constituents. A large number of these constituents is notified for skin sensitisation, and the QSAR toolbox gives various alerts for reactive structures among the constituents which could promote initiation of the adverse outcome pathway for skin sensitisation.
The source substance Ylang Ylang Ext /I /II oil has been classified for skin sensitisation, and based on the composition similarity regarding reactive constituents of the source and target substance, the results for skin sensitisation can be read across to the target substance.
This report follows the RAAF method and so presents:
1) The hypothesis: analogue read-across approach, based on the similarity of the structures and the skin sensitising potential for these types of structures;
2) The scientific justifications (“Assessment Elements”) and their evaluation (“Assessment Options”); which demonstrate the confidence that can be put in this prediction.
3) The conclusions, usable for classification assessment or risk assessment, which are summarised hereafter. - Reason / purpose for cross-reference:
- read-across source
- Positive control results:
- The stimulation index at tested concentrations 5, 10 and 25% w/v were 1.7, 2.3, 6.4, respectively. This result confirms the validity of the test.
- Key result
- Parameter:
- EC3
- Remarks:
- %
- Value:
- 6.8
- Parameter:
- SI
- Value:
- 1.5
- Test group / Remarks:
- 0.5% concentration
- Parameter:
- SI
- Value:
- 1.4
- Test group / Remarks:
- 1% concentration
- Parameter:
- SI
- Value:
- 2.1
- Test group / Remarks:
- 2.5% concentration
- Parameter:
- SI
- Value:
- 2.5
- Test group / Remarks:
- 5% concentration
- Parameter:
- SI
- Value:
- 3.9
- Test group / Remarks:
- 10% concentration
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
Ylang Ylang Extra EO Comores induced a higher than 3-fold increase in lympocyte proliferation at the highest concentration tested (10% w/v).
DETAILS ON STIMULATION INDEX CALCULATION
Mean disintegrations per minute (DPM) values were:
- Vehicle control: 533
- 0.5%: 805
- 1%: 742
- 2.5%: 1099
- 5%: 1331
- 10%: 2090
EC3 CALCULATION
The calculated EC3 was 6.8%.
CLINICAL OBSERVATIONS:
No visual levels of skin irritancy were observed at any of the concentrations used on or around the esar area for the duration of the study.
BODY WEIGHTS
Body weights were recorded but showed no abnormalities. - Interpretation of results:
- other: Skin Sensitiser 1B
- Remarks:
- Based on CLP criteria (Annex I of 1272/2008/EC)
- Conclusions:
- Ylang Ylang Extra EO Comores induced a higher than 3-fold increase in lympocyte proliferation at the highest concentration tested (10% w/v). The calculated EC3 was 6.8%. This result is used for Ylang Ylang III oil, which needs to be classified as Skin Sensitiser Category 1B in accordance with Annex I of the CLP Regulation (1272/2008/EC).
- Executive summary:
A Local Lymph Node Assay (LLNA) was performed according to the OECD guideline 429 (2002). Four mice per group were treated with 0%, 0.5%, 1%, 2.5%, 5%, and 10% w/v Ylang Ylang Extra EO Comores in 1:3 ethanol:diethyl phthalate (vehicle) for three consecutive days, followed by in vivo radiolabelling (by injection) and lymphocyte proliferation analysis with the liquid scintillation counter. The number of disintegrations per minute (dpm) was determined for each group for the pooled lymph nodes. Treatment with Ylang ylang extra EO Comores did induce significantly the lymph node proliferation in mice as compared to controls at the highest dose tested. A higher than 3-fold increase in lympocyte proliferation was found at the highest concentration tested (10% w/v). The calculated EC3 was 6.8%. This result is used for Ylang Ylang III oil, which needs to be classified as Skin Sensitiser Category 1B in accordance with Annex I of the CLP Regulation (1272/2008/EC).
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
A Local Lymph Node Assay (LLNA) was performed according to the OECD guideline 429 (2002). Four mice per group were treated with 0%, 0.5%, 1%, 2.5%, 5%, and 10% w/v Ylang Ylang Extra EO Comores in 1:3 ethanol:diethyl phthalate (vehicle) for three consecutive days, followed byin vivoradiolabelling (by injection) and lymphocyte proliferation analysis with the liquid scintillation counter. The number of disintegrations per minute (dpm) was determined for each group for the pooled lymph nodes. Treatment with Ylang ylang extra EO Comores did induce significantly the lymph node proliferation in mice as compared to controls at the highest dose tested. A higher than 3-fold increase in lympocyte proliferation was found at the highest concentration tested (10% w/v). The calculated EC3 was 6.8%. This result is used for Ylang Ylang III oil, which is considered to be a skin sensitiser.
Justification for classification or non-classification
Based on the available data, Ylang Ylang III oil should be classified for skin sensitisation (Skin Sens. 1B / H317) in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.